123 related articles for article (PubMed ID: 11772450)
21. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
[TBL] [Abstract][Full Text] [Related]
22. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
23. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
24. A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro.
Liang JF; Li YT; Yang VC
Int J Pharm; 2000 Jul; 202(1-2):11-20. PubMed ID: 10915922
[TBL] [Abstract][Full Text] [Related]
25. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen.
Andrade-Gordon P; Strickland S
Biochemistry; 1986 Jul; 25(14):4033-40. PubMed ID: 2943315
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
Zamanlu M; Farhoudi M; Eskandani M; Mahmoudi J; Barar J; Rafi M; Omidi Y
J Drug Target; 2018 Feb; 26(2):95-109. PubMed ID: 28796540
[TBL] [Abstract][Full Text] [Related]
27. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
28. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
[TBL] [Abstract][Full Text] [Related]
29. Heparin but not tissue plasminogen activator improves outcomes in donation after circulatory death liver transplantation in a porcine model.
Hessheimer AJ; Vendrell M; Muñoz J; Ruíz Á; Díaz A; Sigüenza LF; Lanzilotta JR; Delgado Oliver E; Fuster J; Navasa M; García-Valdecasas JC; Taurá P; Fondevila C
Liver Transpl; 2018 May; 24(5):665-676. PubMed ID: 29351369
[TBL] [Abstract][Full Text] [Related]
30. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
31. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
32. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
33. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
[TBL] [Abstract][Full Text] [Related]
35. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
[TBL] [Abstract][Full Text] [Related]
36. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite.
Twomey JA; Peltier GL; Zera RT
J Trauma; 2005 Dec; 59(6):1350-4; discussion 1354-5. PubMed ID: 16394908
[TBL] [Abstract][Full Text] [Related]
37. Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline.
Ryan JM; Key SM; Dumbleton SA; Smith TP
J Vasc Interv Radiol; 2001 Nov; 12(11):1273-7. PubMed ID: 11698625
[TBL] [Abstract][Full Text] [Related]
38. [Properties of protamine-heparin complexes].
Roszkowska W; Worowski K
Acta Haematol Pol; 1979; 10(1):39-46. PubMed ID: 155386
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
40. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M
Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
